Literature DB >> 16322299

Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer.

Amanda Psyrri1, Aris Bamias, Ziwei Yu, Paul M Weinberger, Mohamad Kassar, Sophia Markakis, Diane Kowalski, Eleni Efstathiou, Robert L Camp, David L Rimm, Meletios A Dimopoulos.   

Abstract

PURPOSE: p27 protein is regarded as a valuable prognostic biomarker in cancer with a potential use as a molecular target. However, different methods of immunohistochemical assessment have yielded conflicting results. Here, we sought to determine the prognostic value of p27 in ovarian cancer using a novel method of compartmentalized in situ protein analysis. EXPERIMENTAL
DESIGN: A tissue array composed of 150 advanced stage ovarian cancers uniformly treated, with surgical debulking followed by platinum-paclitaxel combination chemotherapy, was constructed. For evaluation of p27 protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis [automated quantitative analysis (AQUA)].
RESULTS: The mean follow-up time of the patients was 34.3 months. Patients with low Fédération Internationale des Gynaecologistes et Obstetristes stage were more likely to have low nuclear p27 expression (P = 0.008). Low nuclear p27 expression was associated with improved 3-year overall survival (66% versus 20%, P = 0.0047) and disease-free survival (27% versus 12%, P = 0.022). In multivariable analysis, adjusting for well-characterized prognostic variables, low nuclear p27 expression level was the most significant prognostic factor for both disease-free and overall survival.
CONCLUSIONS: Our results indicate that quantitative assessment of nuclear p27 expression level by automated in situ quantitative analysis is a strong predictor for outcome in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322299     DOI: 10.1158/1078-0432.CCR-05-1270

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  12 in total

1.  Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer.

Authors:  Tsang-Chi Lin; Lung-Hung Tsai; Ming-Chih Chou; Chih-Yi Chen; Huei Lee
Journal:  Tumour Biol       Date:  2015-10-20

2.  Cyclin D1 predicts the prognosis of advanced serous ovarian cancer.

Authors:  Tomoko Hashimoto; Nozomu Yanaihara; Aikou Okamoto; Takashi Nikaido; Misato Saito; Satoshi Takakura; Makoto Yasuda; Hiroshi Sasaki; Kazunori Ochiai; Tadao Tanaka
Journal:  Exp Ther Med       Date:  2011-01-18       Impact factor: 2.447

3.  Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays.

Authors:  Viju Ananthanarayanan; Ryan J Deaton; Anup Amatya; Virgilia Macias; Ed Luther; Andre Kajdacsy-Balla; Peter H Gann
Journal:  Hum Pathol       Date:  2011-02-02       Impact factor: 3.466

Review 4.  p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.

Authors:  Seth A Wander; Dekuang Zhao; Joyce M Slingerland
Journal:  Clin Cancer Res       Date:  2010-10-21       Impact factor: 12.531

5.  Rab14 is overexpressed in ovarian cancers and promotes ovarian cancer proliferation through Wnt pathway.

Authors:  Rui Hou; Luo Jiang; Zhuo Yang; Shizhuo Wang; Qifang Liu
Journal:  Tumour Biol       Date:  2016-10-07

6.  Use of combination proteomic analysis to demonstrate molecular similarity of head and neck squamous cell carcinoma arising from different subsites.

Authors:  Paul M Weinberger; Mark Merkley; Jeffrey R Lee; Bao-Ling Adam; Christine G Gourin; Robert H Podolsky; Bruce G Haffty; Evangelia Papadavid; Clarence Sasaki; Amanda Psyrri; William S Dynan
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-07

Review 7.  Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.

Authors:  Sabita N Saldanha; Trygve O Tollefsbol
Journal:  J Cell Physiol       Date:  2014-04       Impact factor: 6.384

8.  Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.

Authors:  Amanda Psyrri; Ju-Whei Lee; Eirini Pectasides; Maria Vassilakopoulou; Efstratios K Kosmidis; Barbara A Burtness; David L Rimm; Harold J Wanebo; Arlene A Forastiere
Journal:  Clin Cancer Res       Date:  2014-04-03       Impact factor: 12.531

9.  Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers.

Authors:  Ashley S Felix; Mark E Sherman; Stephen M Hewitt; Munira Z Gunja; Hannah P Yang; Renata L Cora; Vicky Boudreau; Kris Ylaya; Jolanta Lissowska; Louise A Brinton; Nicolas Wentzensen
Journal:  Front Oncol       Date:  2015-02-09       Impact factor: 6.244

10.  p27 Loss Is Associated with Poor Prognosis in Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Hee Sung Kim; Hye Seung Lee; Kyung Han Nam; Jiwoon Choi; Woo Ho Kim
Journal:  Cancer Res Treat       Date:  2014-07-17       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.